Apr 13, 2024, 09:40
Rami Manochakian: Results of adjuvant Alectinib vs Chemotherapy in resected ALK+ stage IB-IIIA NSCLC
Rami Manochakian, thoracic medical oncologist at Mayo Clinic, shared a post on X:
“Hot off the press.
Just published at NEJM.
Results of ALINA phase 3 trial of adjuvant Alectinib vs Chemotherapy in patients with resected ALK+ stage IB-IIIA Non-Small-Cell Lung Cancer showing: DFS HR: 0.24
2-year DFS: 93% vs 63%”
Source: Rami Manochakian/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 3, 2024, 11:53
Dec 3, 2024, 11:50
Dec 3, 2024, 11:43
Dec 3, 2024, 09:35